Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 5/2014

01-05-2014 | Gynecologic Oncology

Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors

Authors: Letícia da Conceição Braga, Luciana Maria Silva, Josiane Barbosa Piedade, Paulo Traiman, Agnaldo Lopes da Silva Filho

Published in: Archives of Gynecology and Obstetrics | Issue 5/2014

Login to get access

Abstract

Objective

This study assesses TRAIL-R2 (TNF-related apoptosis-inducing ligand receptor 2) and BCL2 (B cell CLL/lymphoma 2) expression as well as CpG island methylation within the TRAIL-R2 promoter in ovarian serous tumors and primary and metastatic serous EOC (epithelial ovarian cancer).

Methods

RNA and DNA were obtained from women with normal ovarian tissues (n = 18), ovarian serous cystadenoma tumors (n = 11) and serous EOC (n = 16) using Trizol®. Quantitative PCR was performed to quantify the relative levels of TRAIL-R2 and BCL2. The methylation frequency of the TRAIL-R3 promoter was assessed using a methylation-specific PCR assay after DNA bisulfite conversion. Differences between the groups were evaluated using the χ 2, Mann–Whitney U or Kruskal–Wallis tests, as indicated.

Results

We identified TRAIL-R2 and BCL2 mRNA expressed in all ovarian tumor groups, and there were significant differences between the groups. Both genes had low expression levels in ovarian serous cystadenoma and primary EOC tumors when compared with metastatic EOC. Methylation of the TRAIL-R2 promoter was frequently observed in all groups; however, there were no statistically significant associations.

Conclusions

Primary EOC is associated with lower TRAIL-R2 and BCL2 expression levels, while metastatic EOC is associated with higher expression of these genes. Promoter DNA methylation was not related to this finding, suggesting there are other mechanisms involved in transcriptional control.
Literature
1.
Bai M, Papoudou-Bai A, Horianopoulos N, Grepi C, Agnantis NJ, Kanavaros P (2007) Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin’s lymphomas. Hum Pathol 38:103–113PubMedCrossRef
2.
Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev 9:415–428CrossRef
3.
Bevis KS, Buchsbaum DJ, Straughn JM Jr (2010) Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol 119:157–163PubMedCrossRef
4.
Braga L, Ramos A, Traiman P, Silva L, Silva-Filho A (2012) TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia. Gynecol Oncol 126:268–273CrossRef
5.
Bras M, Queenan B, Susin SA (2005) Programmed cell death via mitochondria: different modes of dying. Biochemistry 70:231–239PubMed
6.
7.
Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813–820PubMedCrossRef
8.
Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165–1170PubMedCentralPubMedCrossRef
9.
Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B, Mueller W (2009) Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 15:5457–5465PubMedCrossRef
10.
11.
Elrod HA, Fan S, Muller S, Chen GZ, Pan L, Tighiouart M, Shin DM, Khuri FR, Sun SY (2010) Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 5:e12178PubMedCentralPubMedCrossRef
12.
Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39:1462–1475PubMedCrossRef
13.
Fariss MW, Chan CB, Patel M, Van Houten B, Orrenius S (2005) Role of mitochondria in toxic oxidative stress. Mol Interv 5:94–111PubMedCrossRef
14.
FIGO IFoGaO (2009) Clinical practice guidelines
15.
Frankel A, Rosen K, Filmus J, Kerbel RS (2001) Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res 61:4837–4841PubMed
16.
Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811PubMedCrossRef
17.
18.
Hausmann M, Leucht K, Ploner C, Kiessling S, Villunger A, Becker H, Hofmann C, Falk W, Krebs M, Kellermeier S, Fried M, Scholmerich J, Obermeier F, Rogler G (2011) BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. J Biol Chem 286:26533–26540PubMedCentralPubMedCrossRef
19.
20.
Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB (2008) Ovarian cancer: linking genomics to new target discovery and molecular markers: the way ahead. Adv Exp Med Biol 617:23–40PubMedCentralPubMedCrossRef
21.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826PubMedCentralPubMedCrossRef
22.
Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10:356–364PubMedCrossRef
23.
Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288PubMedCrossRef
24.
Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T (2006) Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines. Cancer Lett 241:213–220PubMedCrossRef
25.
Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279:35829–35839PubMedCrossRef
26.
Kelly MM, Hoel BD, Voelkel-Johnson C (2002) Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 1:520–527PubMedCrossRef
27.
Khaider NG, Lane D, Matte I, Rancourt C, Piche A (2012) Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res 2:75–92PubMedCentralPubMed
28.
Kim K, Fisher MJ, Xu SQ, el-Deiry WS (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6:335–346PubMed
29.
Lai JCWJ, Cheng YW, Yeh KT, Wu TC, Chen CY et al (2009) O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells. Anticancer Res 29:6
30.
Li YYF, Hua Y, Lu W, Xie X (2009) Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem 394:7CrossRef
31.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2[−Delta Delta C(T)] method. Methods 25:402–408PubMedCrossRef
32.
33.
Malhi H, Gores GJ (2006) TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25:7333–7335PubMedCrossRef
34.
Mellier G, Huang S, Shenoy K, Pervaiz S (2010) TRAILing death in cancer. Mol Asp Med 31:93–112CrossRef
35.
Meng CFZX, Peng G, Dai DQ (2009) Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol Rep 22:7
36.
Min KJ, Jang JH, Lee JT, Choi KS, Kwon TK (2012) Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J Mol Med (Berl) 90:309–319CrossRef
37.
Nagaprashantha LD, Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS (2011) The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer 128:743–752PubMedCentralPubMedCrossRef
38.
Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM (2007) An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. Cancer 110:297–308PubMedCrossRef
39.
Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815–818PubMedCrossRef
40.
Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2011) Towards novel paradigms for cancer therapy. Oncogene 30:1–20PubMedCrossRef
41.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821PubMedCrossRef
42.
Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109:786–792PubMedCrossRef
43.
Suzuki HGE, Chen W, Anbazhagan R, Van Engeland M, Weijenberg MP et al (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:9CrossRef
44.
Taddei ML, Giannoni E, Fiaschi T, Chiarugi P (2012) Anoikis: an emerging hallmark in health and diseases. J Pathol 226:380–393PubMedCrossRef
45.
Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev 9:231–241CrossRef
46.
Turker MS (2002) Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 21:5388–5393PubMedCrossRef
47.
van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R (2002) Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62:2157–2161PubMed
48.
Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386–5397PubMedCentralPubMedCrossRef
49.
50.
Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV (2010) Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. doi:10.​1186/​1471-2407-10-32
51.
Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev 9:167–181CrossRef
52.
Yerbes R, Palacios C, Lopez-Rivas A (2011) The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin Transl Oncol 13:839–847PubMedCrossRef
Metadata
Title
Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors
Authors
Letícia da Conceição Braga
Luciana Maria Silva
Josiane Barbosa Piedade
Paulo Traiman
Agnaldo Lopes da Silva Filho
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 5/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-3060-0

Other articles of this Issue 5/2014

Archives of Gynecology and Obstetrics 5/2014 Go to the issue

Maternal-Fetal Medicine

Improving patient safety by detecting obstetric care-related adverse events: application of a new screening guide

Gynecologic Oncology

Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience

General Gynecology

Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability

Letter to the Editor

Uterus preservation as an alternative to an emergency hysterectomy for postpartum hemorrhage

Erratum

Erratum to: Colonization of the lower urogenital tract with Ureaplasma parvum can cause asymptomatic infection of the upper reproductive system in women: a preliminary study

Maternal-Fetal Medicine

The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial